Therapy Areas: Central Nervous System
EditForce signs License Agreement with Mitsubishi Tanabe Pharma Corporation
6 July 2022 -

Japan- based drug development company EditForce, Inc. announced on Tuesday that it has signed a License Agreement with Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialise potential gene therapy products for a specific target disease in the field of central nervous system (CNS) by using EditForce's proprietary PPR protein platform technology.

Both companies intend to create potential novel pharmaceuticals for the specific CNS disease by using the drug R&D know-how and global business experience of MTPC and the novel biotechnology of EditForce. MTPC is to acquire the exclusive right to carry out the selection of drug candidate molecules, preclinical and clinical development, manufacturing, and commercialisation worldwide.

According to the terms of the contract, EditForce will receive an upfront payment and milestone payments amounting to more than JPY20bn depending on the development stage and commercialisation progress, and royalties based on global sales after the launch.

EditForce is to proceed with R&D of pharmaceuticals utilising its PPR protein platform technology.




Related Headlines